Skip to main content
OpenTrials
Completed

NCT Number: NCT04918823

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ocular Surface Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

BostonSight

Needham, Massachusetts, 02494, United States

About this study

For this study, all subjects will receive Restasis (Cyclosporine ophthalmic emulsion 0.05%). One drop of the dispensed study drop will be instilled in the PROSE lens reservoir twice a day and the remainder of the reservoir will be filled with normal saline (0.9% sodium chloride solution). In order to standardize solutions used in the PROSE reservoir, all patients recruited will be either currently using or will be switched to buffered preservative-free normal saline (Purilens, Lifestyle Inc., pH 7.46 ) to better match the reported pH of RESTASIS (pH 6.5-8.05 ).

Outcomes will include subjective responses regarding the subject's symptoms and visual function in addition to the objective assessments of the health of the ocular surface seen on clinical examination. Results will be measured at baseline, after 1 week, and after 1 month of the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written Informed Consent has been obtained prior to any study-related procedures taking place
  • Subject is Male or Female, 18 years of age or older prior to the initial visit
  • Is an established wearer of PROSE devices for > 6 months in both eyes
  • Has a finalized PROSE lens design in both eyes, in the opinion of the clinician
  • The PROSE design does NOT include fenestrations
  • Subject requires PROSE devices to treat symptoms and/or signs from underlying dry eye disease, GVHD, Sjogren's syndrome, limbal stem cell deficiency, keratoconjunctivitis sicca, or ocular surface disease
  • Baseline Corneal staining grade of 2 or higher in total, both eyes combined (NEI Grading System) 7
  • Baseline Ocular Surface Disease Index 13 or greater
  • In the opinion of the investigator, the subject can follow study instructions
  • In the opinion of the investigator, the subject can complete all study procedures and visits
  • Able to wear PROSE device continuously for at least 6 hours at a time without removal, in each eye
  • Able to wear PROSE device for at least 10 total hours a day, in each eye
  • Able to wear PROSE device in subsequent continuous sessions of 6 hours, followed by a break to re-instill Restasis in device bowl, followed by another period of continuous wear of at least 4 hours
  • Currently using buffered preservative free normal saline (Purilens) in the device bowl or willing to transition to buffered preservative free normal saline (Purilens) use in the device bowl during the study

Exclusion criteria

  • Is currently participating in any other type of eye-related clinical or research study
  • Is pregnant or nursing as reported by the subject.
  • Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
  • Has had previous ocular surgery within the past 12 weeks.
  • Currently uses or has a prior history of using Restasis in the last 3 months
  • Currently uses or has a prior history of using Cequa in the last 3 months
  • Is currently using Xiidra and has been using Xiidra for less than 3 months
  • Has a history of an allergic reaction or hypersensitivity to any active or inactive ingredient found in Restasis or Cequa or Purilens.
  • Is wearing a PROSE device with Tangible HydraPEG coating
  • The subject is not wearing their PROSE devices daily
  • The subject is only wearing a device for one eye.
  • The participant is monocular
  • The subject wears a PROSE lens with fenestrations
  • The participant carries a diagnosis of glaucoma or ocular hypertension or glaucoma suspect AND is currently using glaucoma medications
  • The participant is NOT able to wear PROSE devices for 6 hours continuously, followed by a break to re-instill Restasis, followed by an additional period of at least 4 hours of continuous wear
  • Allergy to sodium fluorescein
  • Allergy to lissamine green
  • Allergy or intolerance to Purilens solution.

Treatment and study plan

Restasis

Drug

Subject will use one drop of Restasis in the lens before insertion

Other names: cyclosporine ophthalmic solution 0.05%

Primary outcomes

  1. Ocular Surface Disease Index (OSDI) Score Change (1 Month Post Treatment Initiation)

    Time frame: 1 month post initiation change in OSDI score

    The Ocular Surface Disease Index (OSDI) is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease.

  2. Corneal Staining

    Time frame: at baseline and at 1-month post treatment initiation

    Corneal fluorescein staining, pre and post initiation of 0.05% cyclosporine treatment, is measured using the National Eye Institute (NEI) grading system. The NEI grading scale is a system for grading corneal fluorescein staining which divides the corneal surface into 5 areas [central, superior, nasal, inferior, temporal]. A standardized grading system of 0 to 3, with 0 being no staining (better outcome) and 3 being severe staining (worse outcome), is used for each of the areas of cornea. The scores from each corneal area are totaled to determine the total corneal staining score in each eye. The total corneal staining score has a minimum score of zero (better outcome) and a maximum score of 15 (worse outcome) for an individual eye.

  3. Conjunctival Staining

    Time frame: baseline and 1-month post treatment initiation

    Conjunctival fluorescein staining, pre and post initiation of 0.05% cyclosporine treatment, is measured using the National Eye Institute (NEI) grading system. The NEI grading scale is a system for grading conjunctival fluorescein staining which divides the conjunctival surface into 6 areas. A standardized grading system of 0 to 3, with 0 being no staining (better outcome) and 3 being severe staining (worse outcome), is used for each of the areas of conjunctiva. The scores from each conjunctival area are totaled to determine the total conjunctival staining score in each eye. The total conjunctival staining score has a minimum score of zero (better outcome) and a maximum score of 18 (worse outcome) for an individual eye.

  4. Visual Acuity

    Time frame: at baseline and 1-month post treatment initiation

    Subjects vision was tested using Snellen visual acuity chart (converted to LogMAR scale) pre and post initiation of 0.05% cyclosporine treatment. The LogMAR scale ranges from +3.00 to -0.30. A Zero LogMAR indicates standard 20/20 vision. More negative logMAR scale vision indicates better vision. More positive logMAR scale vision indicates worse vision. Legal blindness is defined as a best-corrected visual acuity of +1.0 LogMAR pr worse in the better seeing eye.

  5. Conjunctival Redness

    Time frame: baseline and one month post treatment initiation

    The Efron Grading Scales for Contact Lens Complications includes a standardized method for quantifying the level of conjunctival redness noted on slit lamp examination. The scale ranges, in whole numbers, from 0 to 4, with 0 indicating that conjunctival redness is not present (better outcome) and 4 indicating that the most severe redness is present (worse outcome).

  6. Tolerability Questionnaire Score

    Time frame: baseline and one month post initiation treatment

    Subjects completed questionnaires regarding PROSE device comfort and fit (Tolerability Questionnaire, scale 0 to 10, higher score means better outcome), measured pre and post initiation of 0.05% cyclosporine treatment. Total tolerability score is a composite score sum of SIX questions (maximum score of 60).

  7. Automated Conjunctival Redness Without PROSE Device on the Eye

    Time frame: baseline and one month post treatment initiation

    Conjunctival redness score measured using the automated imaging system Keratograph 5M R-Scan. The Keratograph 5M R-scan is an imaging device which classifies bulbar and limbal conjunctival redness. The R-Scan detects blood vessels in the conjunctiva and evaluates the degree of redness. The minimum score per eye is 0 (no redness present, better outcome), while the maximum score per eye is 4 (most severe redness present, worse outcome).

Sponsors and collaborators

Lead sponsor

Boston Sight

Other

Collaborators

  • Allergan

Registry information

Official study title

Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients With Ocular Surface Disease: A Pilot Study

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jun 9, 2021
Registry last updated
Jan 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.